相关实验视频

Updated: Feb 25, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

蒂卡格勒勒与克洛皮多格勒对患者进行内血管流量转移未破裂的内动脉瘤:一个多中心的调查

Huanwen Chen¹, Dhairya A Lakhani², Marco Colasurdo²

¹From the Department of Neurology (H.C.), MedStar Georgetown University Hospital, Washington DC, USA; Department of Neuroradiology (D.A.L.), West Virginia University, Morgantown WV, USA; Department of Interventional Radiology (M.C.), Oregon Health & Science University, Portland OR, USA; Department of Radiology (A.M.), Yale New Haven Hospital, New Haven CT, USA and Departments of Radiology, Neurosurgery, and Neurology (D.G.), University of Maryland Medical Center, Baltimore MD, USA. Alvin.huanwen.chen@gmail.com.

AJNR. American journal of neuroradiology

|February 23, 2026

概括

提卡格勒勒和克洛皮多格勒在未破裂的内动脉瘤 (UIA) 进行流量转移 (FD) 的患者中显示出类似的缺血性中风和出血风险. 然而,提卡格雷勒与更高的全因死亡风险有关.

科学领域:

神经学神经学
心脏病学心脏病学
血管外科血管外科

背景情况:

在未破裂的内动脉瘤 (UIA) 流量转移 (FD) 后,双重抗血小板治疗至关重要.
作为P2Y12抑制剂的蒂卡格雷勒和克洛皮多格雷尔之间的选择受到争议.
这项研究比较了FD接受UIA患者的蒂卡格罗和克洛皮多格雷尔.

研究的目的:

为了比较Ticagrelor与Clopidogrel在因UIA而接受FD的患者中的有效性.
评估与每个P2Y12抑制剂相关的缺血性中风,出血和死亡风险.

主要方法:

从TrinetX平台对现实世界的临床记录进行了回顾性倾向得分匹配分析.
包括患有UIA的成年患者,他们接受了FD并接受了ticagrelor或clopidogrel.
主要终点:缺血性中风;次要终点:大出血 (ICH或输血),ICH,所有原因死亡率180天.

主要成果:

在匹配后,每组有963名患者 (蒂卡格勒勒与克洛皮多格勒).
缺血性中风的发生率相似 (1.3%对1.3%,p=1.00).
大型出血 (2.4%对2.0%,p=0.52) 和ICH (1.4%对0.8%,p=0.18) 的发生率在数字上更高.
所有原因的死亡率在提卡格勒勒 (1.7%对比0.6%,p=0.025) 显著更高.

结论:

蒂卡格勒罗和克洛皮多格雷尔在用FD治疗的UIA患者中显示出缺血性中风和出血的同等风险.
与克洛皮多格雷尔相比,提卡格雷勒的使用与所有原因死亡的风险显著增加有关.
实际数据表明,在这种患者群体中,要仔细考虑选择P2Y12抑制剂.

更多相关视频

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms

Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms

Published on: August 11, 2015

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...